Planning study
Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish Breast Cancer Group (DBCG) HYPO trial
Thomsen MS, Berg M, Zimmermann S, et al. · Danish Breast Cancer Group (DBCG)
DoseLab summary
Quality assessment of treatment plans from the randomized DBCG HYPO trial (whole breast, 50 Gy in 25 fractions vs 40 Gy in 15 fractions). It lists the trial's limits for the breast target, ipsilateral lung, heart and LAD (called LADCA), reports compliance, and suggests stricter lung and heart limits for future whole-breast planning. LAD delineation was optional in the trial.
Why this is useful
The DBCG HYPO trial's organ limits for 50 Gy/25 and 40 Gy/15 whole-breast plans — including an LAD maximum dose — and how well 1,854 plans met them.
Reference details
- Title
- Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish Breast Cancer Group (DBCG) HYPO trial
- Authors / organization
- Thomsen MS, Berg M, Zimmermann S, et al. · Danish Breast Cancer Group (DBCG)
- Publication / protocol
- Clin Transl Radiat Oncol. 2021;28:118–123
- Version
- Pending verification
- Year
- 2021
- DOI
- 10.1016/j.ctro.2021.03.009
- Disease sites
- Breast
- Topics
- Breast, Whole breast, Hypofractionation, Heart, LAD, Dose Constraints, Plan Evaluation
- Fractionation context
- Whole breast, 50 Gy/25 fx vs 40 Gy/15 fx
- Last reviewed by DoseLab
- 2026-09-23